文献速递淋巴瘤

淋巴瘤免疫微环境与免疫检查点阻断治疗反应

The immune landscape and response to immune checkpoint blockade therapy in lymphoma.
PubMed 文献 · Blood · 2020-01-01

该综述描述了主要B细胞淋巴瘤的免疫微环境特征及其与免疫检查点阻断治疗(CBT)反应的关系。经典霍奇金淋巴瘤和原发纵隔B细胞淋巴瘤对CBT敏感,而滤泡性淋巴瘤和弥漫大B细胞淋巴瘤反应较差。文章强调需开发预测CBT敏感性的生物标志物。

要点

  • 经典霍奇金淋巴瘤具有炎症微环境和免疫逃逸遗传改变,对PD-1阻断敏感。
  • 滤泡性淋巴瘤和多数弥漫大B细胞淋巴瘤缺乏免疫监视措施,抗PD-1治疗反应较差。
  • 需开发预测淋巴瘤患者CBT敏感性的生物标志物。

核心结论

  • 淋巴瘤对免疫检查点阻断治疗的反应差异与肿瘤免疫微环境特征及免疫逃逸通路相关。

研究设计与样本

  • 综述,描述主要B细胞淋巴瘤的免疫微环境及免疫逃逸通路,并讨论肿瘤遗传改变对免疫环境的影响。

主要发现

  • 经典霍奇金淋巴瘤以炎症环境、免疫逃逸遗传改变和对PD-1阻断敏感为特征。
  • 滤泡性淋巴瘤和多数弥漫大B细胞淋巴瘤缺乏免疫监视措施,抗PD-1治疗反应较差。

临床怎么用

  • 需依据淋巴瘤免疫微环境特征识别可能从CBT获益的亚组。
  • 未来需开发预测CBT敏感性的生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The clinical development of effective cancer immunotherapies, along with advances in genomic analysis, has led to the identification of tumor environmental features that predict for sensitivity to immune checkpoint blockade therapy (CBT). Early-phase clinical trial results have demonstrated the remarkable effectiveness of CBT in specific lymphoma subtypes, including classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma. Conversely, CBT has been relatively disappointing in follicular lymphoma and diffuse large B-cell lymphoma. These clinical observations, coupled with important scientific discoveries, have uncovered salient features of the lymphoma microenvironment that correlate with immunotherapy response in patients. For example, classical Hodgkin lymphoma is characterized by an inflammatory environment, genetic alterations that facilitate escape from immune attack, and sensitivity to PD-1 blockade therapy. On the other hand, for lymphomas in which measures of immune surveillance are lacking, including follicular lymphoma and most diffuse large B-cell lymphomas, anti-PD-1 therapy has been less effective. An improved understanding of the immune landscapes of these lymphomas is needed to define subsets that might benefit from CBT. In this article, we describe the immune environments associated with major B-cell lymphomas with an emphasis on the immune escape pathways orchestrated by these diseases. We also discuss how oncogenic alterations in lymphoma cells may affect the cellular composition of the immune environment and ultimately, vulnerability to CBT. Finally, we highlight key areas for future investigation, including the need for the development of biomarkers that predict for sensitivity to CBT in lymphoma patients.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Kline J, Godfrey J, Ansell SM, et al. The immune landscape and response to immune checkpoint blockade therapy in lymphoma. Blood. 2020. PMID: 31790142. doi:10.1182/blood.2019000847

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。